Amicorp FS Faces Trading Suspension Over Delayed 2025 Accounts
Trading suspension for Amicorp FS as audit delayed by operational shift; Board confirms no FY25 irregularities.
This article covers information on Amicorp FS (UK) PLC.
LON:AMIFAmicorp FS trading suspension after audit delay: what’s going on and why it matters
Amicorp FS (UK) Plc has told the market it will miss the 30 April 2026 deadline to publish its audited results for the year ended 31 December 2025. The Board has agreed with its auditor, BDO, that the FY25 audit won’t be wrapped up in time, and the Company has applied for a temporary suspension of its listing from 7.30 am on 1 May 2026 until those results are published.
The stated cause is operational: a planned shift of work from Bangalore to Cape Town created unforeseen complexities that slowed the audit. Management says the transition has completed. Crucially, the Board reaffirms that the delay is administrative only and does not indicate any irregularities in the FY25 numbers.
Why the FY25 results are delayed: Bangalore to Cape Town migration
Amicorp FS has been moving operations from Bangalore to Cape Town. That kind of migration – especially near a year end – can tangle up audit trails, data access, and control testing. The Company says these complexities extended the audit timetable.
The move is now complete, which should help future reporting run smoother. But the immediate impact is a longer-than-expected audit, and therefore a missed regulatory deadline.
Temporary suspension of listing: what it means for shareholders
The Company has asked the FCA to suspend trading in its ordinary shares (US$1.00 nominal value) from 7.30 am on 1 May 2026. During a suspension, the shares won’t trade – no buying or selling – until the suspension is lifted.
In practice, this pauses price discovery and liquidity. When trading resumes after results land, price action can be jumpy as the market digests the new information. The RNS does not give a new publication date, only that an update will follow “in due course”.
DTR 4.1.3R in plain English: the reporting clock
Under the FCA’s Disclosure Guidance and Transparency Rules (DTR 4.1.3R), companies with a 31 December year end must publish their audited annual financial report within four months – by 30 April. Missing that deadline typically leads to a temporary suspension until the report is out, which is exactly what Amicorp FS is preparing for.
Audit status and Board reassurance
BDO is the auditor. The Company says it is working with BDO to finalise the audit and reiterates guidance from its 27 February 2026 trading update: the Group is focused on organic growth and remains positive on the outlook. Importantly, the Board states the delay is due to administrative matters and “does not indicate any irregularities” in the FY25 results.
That is reassuring, but until the signed accounts are published, investors do not have the final audited numbers or notes. The statement is clear; the verification is pending.
Key dates and facts from the RNS
| Financial year | Year ended 31 December 2025 (FY25) |
| Regulatory deadline | 30 April 2026 (DTR 4.1.3R) |
| Expected action | Temporary suspension from 7.30 am on 1 May 2026 |
| Audit firm | BDO LLP |
| Reason for delay | Operational transition from Bangalore to Cape Town created unforeseen complexities, extending the audit |
| Transition status | Completed |
| New results date | Not disclosed |
| Board’s stance | Administrative delay only; no irregularities indicated; organic growth focus; positive outlook |
| Listing | Official List of the FCA; ordinary shares of US$1.00 each |
My take: the good, the bad, and the near-term watchlist
Positives to note
- Clear, specific cause for the delay: the Bangalore-to-Cape Town migration explains the operational friction.
- Transition completed: reduces the risk of prolonged operational disruption.
- Explicit statement of no irregularities in FY25 results: a strong reassurance from the Board.
What tempers enthusiasm
- No revised publication date: uncertainty lingers until BDO signs off.
- Suspension is never ideal: it halts liquidity and tends to dent investor confidence in the short term.
- Audit dependencies: even administrative delays can sometimes surface follow-on queries; until the report is out, that risk isn’t fully closed.
What I’m watching next
- The next RNS setting a firm publication date for the FY25 audited report.
- Any commentary on audit progress from BDO via the Company.
- Disclosures in the final report around internal controls and the operational migration, to gauge whether additional investment is needed to bed down processes.
Quick refresher: what Amicorp FS actually does
Amicorp FS is an international specialist fund services group serving institutional investors, fund managers (private equity, venture capital and hedge funds), and family offices. It provides services to over 330 funds, underpinned by market-recognised technology.
- Fund Administration and Investor Services: fund accounting, in-house NAV calculation, investor registry and transfer agency, subscriptions/redemptions booking, audit liaison, and real-time oversight.
- Governance and Compliance: FATCA/CRS reporting, fiduciary and AML officer services, and administrative support to boards and committees.
- BPO Services: automated accounting and administration for funds and SPVs, corporate accounting, debt and loan administration, data sourcing, CFO support, and regular management reporting.
Bottom line: a procedural snag with real-world consequences
This looks like an operationally driven audit delay rather than a financial integrity issue, per the Board’s statement. Even so, a temporary suspension is a serious step that freezes trading and can create a sentiment overhang until clarity arrives.
If the audit completes swiftly and the results land without surprises, the impact should be contained. The longer the gap, the more attention will turn to audit findings and control disclosures. For now, the key is a timely, dated follow-up RNS and the publication of those FY25 accounts.
Related
Keep reading
Investing
AstraZeneca’s Enhertu delivers Phase III lung cancer PFS win
Enhertu delayed disease progression versus standard care in a Phase III lung cancer trial, supporting its potential move into first-line treatment.
JoshuaAugust 17, 2026
Investing
Optima Health FY26 results: growth beats expectations as PAM integration begins
Optima Health beat adjusted EBITDA expectations in FY26, while the £100 million PAM acquisition reshaped its growth prospects and balance sheet.
JoshuaAugust 17, 2026
Investing
Nostrum Oil & Gas Agrees $304.6 Million Kazakhstan Sale Ahead of Wind-Down
Nostrum plans to sell its Kazakhstan operations, repay secured notes in full and begin an orderly wind-down after completion.
JoshuaAugust 17, 2026
Last updated
Category
InvestingLikes
Star Rating
No ratings yet
Comments
No comments yet - start the conversation.